400
Participants
Start Date
November 17, 2023
Primary Completion Date
April 30, 2026
Study Completion Date
January 31, 2028
Jelmyto (mitomycin) for pyelocalyceal solution
"The dose of Jelmyto to be instilled is 4 mg per mL via ureteral catheter or a nephrostomy tube, with total instillation volume based on volumetric measurements using pyelography, not to exceed 15 mL (60 mg of mitomycin).~Instill Jelmyto once weekly for six weeks. For patients with a complete response 3 months after Jelmyto initiation, Jelmyto instillations may be administered once a month for a maximum of 11 additional instillations."
RECRUITING
NYU Grossman School of Medicine, New York
RECRUITING
The Feinstein Institutes for Medical Research, Lake Success
RECRUITING
SUNY Upstate, Syracuse
RECRUITING
Chesapeake Urology, Baltimore
RECRUITING
Johns Hopkins Medical Center, Baltimore
RECRUITING
The University of North Carolina Chapel Hill, Chapel Hill
RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
University of Florida, Gainesville
RECRUITING
Mount Sinai Medical Center of Florida, Inc., Miami
RECRUITING
H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., Tampa
RECRUITING
Ohio State University, Columbus
RECRUITING
Indiana University, Indianapolis
RECRUITING
University of Michigan, Ann Arbor
RECRUITING
The State University of Iowa, Iowa City
RECRUITING
Northwestern University, Chicago
RECRUITING
University of Missouri, Columbia
RECRUITING
UT Southwestern Medical Center, Dallas
RECRUITING
The University of Texas M.D. Anderson Cancer Center, Houston
RECRUITING
Providence St. Johns Health Center, Santa Monica
RECRUITING
Mass General Hospital (MGH), Boston
RECRUITING
The Brigham and Womens Hospital, Boston
RECRUITING
Rutgers, New Brunswick
UroGen Pharma Ltd.
INDUSTRY